Clinical Trials Logo

Filter by:
NCT ID: NCT03486301 Active, not recruiting - Tumor, Solid Clinical Trials

BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

Start date: February 15, 2018
Phase: Phase 1
Study type: Interventional

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors

NCT ID: NCT03486067 Active, not recruiting - Multiple Myeloma Clinical Trials

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Start date: April 3, 2018
Phase: Phase 1
Study type: Interventional

Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.

NCT ID: NCT03485963 Active, not recruiting - HIV Infections Clinical Trials

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

RESIST
Start date: March 21, 2019
Phase: Phase 1
Study type: Interventional

This is a phase I, multi-site, study of the safety, immunologic and virologic responses of ex vivo expanded HIV-1 multi-antigen specific T-cell therapy (HST-NEET) as a therapeutic strategy in HIV-infected individuals suppressed on antiretroviral therapy (ART).

NCT ID: NCT03485820 Active, not recruiting - Ischemic Stroke Clinical Trials

A Novel Transition Program to Reduce Disability After Stroke

COMPASS
Start date: January 20, 2018
Phase: N/A
Study type: Interventional

This study evaluates a program designed to help individuals transition home from inpatient rehabilitation following an ischemic or hemorrhagic stroke. Half of the participants will receive a stroke education program while the other half will receive an environmental modifications program.

NCT ID: NCT03485729 Active, not recruiting - Clinical trials for Endometrial Cancer Recurrent

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Start date: March 21, 2018
Phase: Phase 2
Study type: Interventional

This is a a Simon's two-stage, non-randomized, open label, 2-arm Phase II trial of ONC201 in women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior chemotherapy regimen.

NCT ID: NCT03485547 Active, not recruiting - Clinical trials for Blastic Plasmacytoid Dendritic Cell Neoplasm

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Start date: August 23, 2018
Phase: Phase 1
Study type: Interventional

This research study is studying a drug as a possible treatment for BPDCN. The intervention involved in this study is: Venetoclax

NCT ID: NCT03484884 Active, not recruiting - Thyroid Cancer Clinical Trials

A Study of Optical Imaging With Light From Radiotracers in Cancer Patients

Start date: March 20, 2018
Phase:
Study type: Observational

The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.

NCT ID: NCT03484819 Active, not recruiting - Clinical trials for Refractory Diffuse Large B-Cell Lymphoma

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Start date: December 13, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well copanlisib hydrochloride and nivolumab work in treating patients with diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma that has come back (recurrent) or does not responded to the treatment (refractory). Copanlisib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving copanlisib hydrochloride and nivolumab may work better in treating patients with diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma compared to standard of care.

NCT ID: NCT03484598 Active, not recruiting - Epilepsy Clinical Trials

Clinical Utility of the SPEAC® System: A Case Series

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

The primary objective is to collect preliminary data related to the clinical utility of the SPEAC System in patients with a history of motor seizures. This trial is primarily an observational investigation. This protocol describes a series of observational case studies. Each case study is intended to be interpreted independent from the other case studies. Self-reported seizure frequency will be compared to observed seizure frequency using the SPEAC System.

NCT ID: NCT03484494 Active, not recruiting - Bipolar Disorder Clinical Trials

Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression

LFMSBioMGeri
Start date: May 29, 2018
Phase: N/A
Study type: Interventional

The protocol involves functional Magnetic Resonance Imaging acquisitions immediately before and after Low Field Magnetic Stimulation treatment on two separate days in a sham controlled, randomized trial, in order to assess the physiologic effects of Low Field Magnetic Stimulation on brain function in a geriatric population with bipolar depression.